» Articles » PMID: 12774921

Oxidative Stress and the Myelodysplastic Syndromes

Overview
Journal Int J Hematol
Specialty Hematology
Date 2003 May 31
PMID 12774921
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

The evolution of higher organisms from anaerobic to aerobic living has promoted an elaborate mechanism of defense against potentially toxic oxidants. Many environmental toxicants implicated in the pathogenesis of myelodysplastic syndromes (MDS), including benzene and ionizing radiation, exert toxicity via pro-oxidant mechanisms. The emerging data suggest a probable genetic susceptibility to environmental carcinogenesis through functional polymorphic variants in enzymes that metabolize toxicants and/or protect against oxidative stress. The most studied enzyme is NAD(P)H:quinone oxidoreductase (NQO1). CD34+ cells from individuals homozygous for the NQO1 C609T nonfunctional allelic variant are incapable of enzyme induction following exposure to benzene, thus potentially increasing the hematotoxicity of benzene metabolites. Serologic and molecular markers of oxidative stress are present in many patients with MDS and include an increased concentration of the lipid peroxidation product malondialdehyde and the presence of oxidized bases in CD34+ cells. Potential mechanisms of oxidative stress include mitochondrial dysfunction via iron overload and mitochondrial DNA mutation, systemic inflammation, and bone marrow stromal defects. The biological activity of the antioxidant aminothiol amifostine in vivo suggests that these pathways may be meaningful targets for future therapy in MDS patients.

Citing Articles

Redox biomarker levels in patients with myelodysplastic syndrome.

Tsiara E, Makri S, Skaperda Z, Giannakoulas N, Vasilopoulos G, Kouretas D Biomed Rep. 2025; 22(3):45.

PMID: 39882334 PMC: 11775644. DOI: 10.3892/br.2025.1923.


Role of reactive oxygen species in myelodysplastic syndromes.

Jing Q, Zhou C, Zhang J, Zhang P, Wu Y, Zhou J Cell Mol Biol Lett. 2024; 29(1):53.

PMID: 38616283 PMC: 11017617. DOI: 10.1186/s11658-024-00570-0.


Iron overload induces dysplastic erythropoiesis and features of myelodysplasia in Nrf2-deficient mice.

Duarte T, Lopes M, Oliveira M, Santos A, Vasco C, Reis J Leukemia. 2023; 38(1):96-108.

PMID: 37857886 DOI: 10.1038/s41375-023-02067-9.


Expression Changes of SIRT1 and FOXO3a Significantly Correlate with Oxidative Stress Resistance Genes in AML Patients.

Mizani S, Keshavarz A, Vazifeh Shiran N, Bashash D, Farsani M Indian J Hematol Blood Transfus. 2023; 39(3):392-401.

PMID: 37304466 PMC: 10247606. DOI: 10.1007/s12288-022-01612-3.


A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes.

Wang Y, Hou H, Lin C, Kuo Y, Yao C, Hsu C Blood Adv. 2021; 5(22):4535-4548.

PMID: 34614508 PMC: 8759137. DOI: 10.1182/bloodadvances.2021005141.


References
1.
Rothman N, Smith M, Hayes R, Traver R, Hoener B, Campleman S . Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997; 57(14):2839-42. View

2.
Bjork J, Albin M, Mauritzson N, Stromberg U, Johansson B, Hagmar L . Smoking and myelodysplastic syndromes. Epidemiology. 2000; 11(3):285-91. DOI: 10.1097/00001648-200005000-00010. View

3.
Jonasova A, Neuwirtova R, cermak J, Vozobulova V, Mocikova K, Siskova M . Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998; 100(2):304-9. DOI: 10.1046/j.1365-2141.1998.00551.x. View

4.
Maciejewski J, Selleri C, Sato T, Anderson S, Young N . Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol. 1995; 91(1):245-52. DOI: 10.1111/j.1365-2141.1995.tb05277.x. View

5.
Kitagawa M, Takahashi M, Yamaguchi S, Inoue M, Ogawa S, Hirokawa K . Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes. Leukemia. 1999; 13(5):699-703. DOI: 10.1038/sj.leu.2401407. View